Percutaneous extracorporeal arteriovenous carbon dioxide removal improves survival in respiratory distress syndrome: A prospective randomized outcomes study in adult sheep

Joseph B. Zwischenberger, Scott K. Alpard, Weike Tao, Donald J. Deyo, Akhil Bidani

    Research output: Contribution to journalArticle

    43 Citations (Scopus)

    Abstract

    Objective: Arteriovenous carbon dioxide removal (AVCO2R) uses a simple arteriovenous shunt for CO2 removal to minimize barotrauma/volutrauma from mechanical ventilation. We performed a prospective randomized outcomes study of AVCO2R in our new, clinically relevant model of respiratory distress syndrome. Methods: Adult sheep (n = 18) received an LD50 severe smoke inhalation and 40% third-degree burn. When respiratory distress syndrome developed (PaO2/FIO2 < 200 at 40 to 48 hours), animals were randomized to the AVCO2R (n = 9) or sham group (n = 9) for 7 days. Ventilator management protocols mandated reductions in minute ventilation, first tidal volume to peak inspiratory pressure less than 30 cm H2O, then respiratory rate when PaCO2 was less than 40 mm Hg. Pao2 was kept above 60 mm Hg by adjusting FIO2. When FIO2 was 0.21, animals were weaned. Results: The study required 2946 animal-hours of critical care with 696 AVCO2R hours. One died in each group during model development. AVCO2R flow from 820 mL/min to 970 mL/min (11% to 14% cardiac output) removed CO2 at a rate of 92 to 116 mL/min (mean 103 mL/min; 93%-97% of CO2 production). Heart rate, mean arterial pressure, cardiac output, and pulmonary arterial wedge pressure remained relatively constant. Within 48 hours, AVCO2R allowed significant ventilator reductions versus baseline in the following measurements: tidal volume (420 to 270 mL), peak inspiratory pressure (25 to 14 cm H2O), minute ventilation (13 to 5 L/min), respiratory rate (26 to 16 breaths/min), and FIO2 (0.88 to 0.35). Ventilator-free days with AVCO2R were 3.9 versus 0.2 (P < .01) for sham animals, and ventilator-dependent days with AVCO2R were 2.4 versus 6.2 (P < .01) for the 3 sham survivors. All 8 AVCO2R animals and 3 of 8 sham animals survived 7 days after randomization. Conclusions: Percutaneous AVCO2R achieved significant reduction in airway pressures, increased ventilator-free days, decreased ventilator-dependent days, and improved survival in a sheep model of respiratory distress syndrome.

    Original languageEnglish (US)
    Pages (from-to)542-551
    Number of pages10
    JournalJournal of Thoracic and Cardiovascular Surgery
    Volume121
    Issue number3
    DOIs
    StatePublished - 2001

    Fingerprint

    Mechanical Ventilators
    Carbon Dioxide
    Sheep
    Outcome Assessment (Health Care)
    Tidal Volume
    Respiratory Rate
    Pressure
    Cardiac Output
    Ventilation
    Arterial Pressure
    Barotrauma
    Pulmonary Wedge Pressure
    Lethal Dose 50
    Critical Care
    Random Allocation
    Artificial Respiration
    Smoke
    Inhalation
    Heart Rate

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine
    • Surgery

    Cite this

    Percutaneous extracorporeal arteriovenous carbon dioxide removal improves survival in respiratory distress syndrome : A prospective randomized outcomes study in adult sheep. / Zwischenberger, Joseph B.; Alpard, Scott K.; Tao, Weike; Deyo, Donald J.; Bidani, Akhil.

    In: Journal of Thoracic and Cardiovascular Surgery, Vol. 121, No. 3, 2001, p. 542-551.

    Research output: Contribution to journalArticle

    @article{65c850d18ff44a7781eeef38da0290fd,
    title = "Percutaneous extracorporeal arteriovenous carbon dioxide removal improves survival in respiratory distress syndrome: A prospective randomized outcomes study in adult sheep",
    abstract = "Objective: Arteriovenous carbon dioxide removal (AVCO2R) uses a simple arteriovenous shunt for CO2 removal to minimize barotrauma/volutrauma from mechanical ventilation. We performed a prospective randomized outcomes study of AVCO2R in our new, clinically relevant model of respiratory distress syndrome. Methods: Adult sheep (n = 18) received an LD50 severe smoke inhalation and 40{\%} third-degree burn. When respiratory distress syndrome developed (PaO2/FIO2 < 200 at 40 to 48 hours), animals were randomized to the AVCO2R (n = 9) or sham group (n = 9) for 7 days. Ventilator management protocols mandated reductions in minute ventilation, first tidal volume to peak inspiratory pressure less than 30 cm H2O, then respiratory rate when PaCO2 was less than 40 mm Hg. Pao2 was kept above 60 mm Hg by adjusting FIO2. When FIO2 was 0.21, animals were weaned. Results: The study required 2946 animal-hours of critical care with 696 AVCO2R hours. One died in each group during model development. AVCO2R flow from 820 mL/min to 970 mL/min (11{\%} to 14{\%} cardiac output) removed CO2 at a rate of 92 to 116 mL/min (mean 103 mL/min; 93{\%}-97{\%} of CO2 production). Heart rate, mean arterial pressure, cardiac output, and pulmonary arterial wedge pressure remained relatively constant. Within 48 hours, AVCO2R allowed significant ventilator reductions versus baseline in the following measurements: tidal volume (420 to 270 mL), peak inspiratory pressure (25 to 14 cm H2O), minute ventilation (13 to 5 L/min), respiratory rate (26 to 16 breaths/min), and FIO2 (0.88 to 0.35). Ventilator-free days with AVCO2R were 3.9 versus 0.2 (P < .01) for sham animals, and ventilator-dependent days with AVCO2R were 2.4 versus 6.2 (P < .01) for the 3 sham survivors. All 8 AVCO2R animals and 3 of 8 sham animals survived 7 days after randomization. Conclusions: Percutaneous AVCO2R achieved significant reduction in airway pressures, increased ventilator-free days, decreased ventilator-dependent days, and improved survival in a sheep model of respiratory distress syndrome.",
    author = "Zwischenberger, {Joseph B.} and Alpard, {Scott K.} and Weike Tao and Deyo, {Donald J.} and Akhil Bidani",
    year = "2001",
    doi = "10.1067/mtc.2001.112828",
    language = "English (US)",
    volume = "121",
    pages = "542--551",
    journal = "Journal of Thoracic and Cardiovascular Surgery",
    issn = "0022-5223",
    publisher = "Mosby Inc.",
    number = "3",

    }

    TY - JOUR

    T1 - Percutaneous extracorporeal arteriovenous carbon dioxide removal improves survival in respiratory distress syndrome

    T2 - A prospective randomized outcomes study in adult sheep

    AU - Zwischenberger, Joseph B.

    AU - Alpard, Scott K.

    AU - Tao, Weike

    AU - Deyo, Donald J.

    AU - Bidani, Akhil

    PY - 2001

    Y1 - 2001

    N2 - Objective: Arteriovenous carbon dioxide removal (AVCO2R) uses a simple arteriovenous shunt for CO2 removal to minimize barotrauma/volutrauma from mechanical ventilation. We performed a prospective randomized outcomes study of AVCO2R in our new, clinically relevant model of respiratory distress syndrome. Methods: Adult sheep (n = 18) received an LD50 severe smoke inhalation and 40% third-degree burn. When respiratory distress syndrome developed (PaO2/FIO2 < 200 at 40 to 48 hours), animals were randomized to the AVCO2R (n = 9) or sham group (n = 9) for 7 days. Ventilator management protocols mandated reductions in minute ventilation, first tidal volume to peak inspiratory pressure less than 30 cm H2O, then respiratory rate when PaCO2 was less than 40 mm Hg. Pao2 was kept above 60 mm Hg by adjusting FIO2. When FIO2 was 0.21, animals were weaned. Results: The study required 2946 animal-hours of critical care with 696 AVCO2R hours. One died in each group during model development. AVCO2R flow from 820 mL/min to 970 mL/min (11% to 14% cardiac output) removed CO2 at a rate of 92 to 116 mL/min (mean 103 mL/min; 93%-97% of CO2 production). Heart rate, mean arterial pressure, cardiac output, and pulmonary arterial wedge pressure remained relatively constant. Within 48 hours, AVCO2R allowed significant ventilator reductions versus baseline in the following measurements: tidal volume (420 to 270 mL), peak inspiratory pressure (25 to 14 cm H2O), minute ventilation (13 to 5 L/min), respiratory rate (26 to 16 breaths/min), and FIO2 (0.88 to 0.35). Ventilator-free days with AVCO2R were 3.9 versus 0.2 (P < .01) for sham animals, and ventilator-dependent days with AVCO2R were 2.4 versus 6.2 (P < .01) for the 3 sham survivors. All 8 AVCO2R animals and 3 of 8 sham animals survived 7 days after randomization. Conclusions: Percutaneous AVCO2R achieved significant reduction in airway pressures, increased ventilator-free days, decreased ventilator-dependent days, and improved survival in a sheep model of respiratory distress syndrome.

    AB - Objective: Arteriovenous carbon dioxide removal (AVCO2R) uses a simple arteriovenous shunt for CO2 removal to minimize barotrauma/volutrauma from mechanical ventilation. We performed a prospective randomized outcomes study of AVCO2R in our new, clinically relevant model of respiratory distress syndrome. Methods: Adult sheep (n = 18) received an LD50 severe smoke inhalation and 40% third-degree burn. When respiratory distress syndrome developed (PaO2/FIO2 < 200 at 40 to 48 hours), animals were randomized to the AVCO2R (n = 9) or sham group (n = 9) for 7 days. Ventilator management protocols mandated reductions in minute ventilation, first tidal volume to peak inspiratory pressure less than 30 cm H2O, then respiratory rate when PaCO2 was less than 40 mm Hg. Pao2 was kept above 60 mm Hg by adjusting FIO2. When FIO2 was 0.21, animals were weaned. Results: The study required 2946 animal-hours of critical care with 696 AVCO2R hours. One died in each group during model development. AVCO2R flow from 820 mL/min to 970 mL/min (11% to 14% cardiac output) removed CO2 at a rate of 92 to 116 mL/min (mean 103 mL/min; 93%-97% of CO2 production). Heart rate, mean arterial pressure, cardiac output, and pulmonary arterial wedge pressure remained relatively constant. Within 48 hours, AVCO2R allowed significant ventilator reductions versus baseline in the following measurements: tidal volume (420 to 270 mL), peak inspiratory pressure (25 to 14 cm H2O), minute ventilation (13 to 5 L/min), respiratory rate (26 to 16 breaths/min), and FIO2 (0.88 to 0.35). Ventilator-free days with AVCO2R were 3.9 versus 0.2 (P < .01) for sham animals, and ventilator-dependent days with AVCO2R were 2.4 versus 6.2 (P < .01) for the 3 sham survivors. All 8 AVCO2R animals and 3 of 8 sham animals survived 7 days after randomization. Conclusions: Percutaneous AVCO2R achieved significant reduction in airway pressures, increased ventilator-free days, decreased ventilator-dependent days, and improved survival in a sheep model of respiratory distress syndrome.

    UR - http://www.scopus.com/inward/record.url?scp=0035076052&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0035076052&partnerID=8YFLogxK

    U2 - 10.1067/mtc.2001.112828

    DO - 10.1067/mtc.2001.112828

    M3 - Article

    C2 - 11241090

    AN - SCOPUS:0035076052

    VL - 121

    SP - 542

    EP - 551

    JO - Journal of Thoracic and Cardiovascular Surgery

    JF - Journal of Thoracic and Cardiovascular Surgery

    SN - 0022-5223

    IS - 3

    ER -